Pharmaceuticals
Fapon Biopharma's Anti-CD47 Antibody FP002 Earns IND Approval from FDA
SHENZHEN, China, Feb. 22, 2023 /PRNewswire/ -- Fapon Biopharma, an innovative biotech company, announced today that its Investigational New Drug (IND) application of FP002, an anti-CD47 monoclonal antibody drug candidate, has been approved by FDA for clinical trials. FP002 is a humanized anti-CD...
Commercialization of Gene Therapy is coming soon: Neurophth Completes Patient Enrollment for Phase III clinical trial for the gene therapy treatment of LHON
WUHAN, China and SAN DIEGO, Feb. 21, 2023 /PRNewswire/ -- Neurophth Therapeutics, Inc. ("Neurophth") announced today thatthe last patient has been enrolled in the Phase III clinical trial for the treatment of Leber hereditary optic neuropathy (LHON) inChina. It marks the completion of patient enr...
NMPA accepted the registration applications for Uro-G and Uro-3500
SHANGHAI, Feb. 21, 2023 /PRNewswire/ -- Asieris Pharmaceuticals (688176), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced that the registration applications for ...
RVAC Medicines Secures HSA Approval to Initiate Phase 1B Clinical Trial in Singapore
SINGAPORE, Feb. 20, 2023 /PRNewswire/ -- RVAC Medicines Pte. Ltd. (RVAC), a messenger RNA (mRNA) technology platform company, announced today that it has secured the approval from the Health Sciences Authority (HSA) to initiate Phase 1B clinical trial in Singapore to evaluate the safety and immuno...
Bridge Biotherapeutics Presents Phase 2a Clinical Trial Results For BBT-401, a Drug Candidate to Treat Ulcerative Colitis
* BBT-401 meets safety endpoints achieved in previous clinical studies * The drug candidate did not achieve an improved clinical response compared to the placebo study group * 54.5% of the treatment cohort exhibited a valid treatment response to orally administered BBT-401 SEONGNAM, South Ko...
EDAN Pictured the Long-Term Regional Development Plans with the Minister Counselor of the Chinese Embassy in Kenya
NAIROBI, Kenya, Feb. 20, 2023 /PRNewswire/ -- Minister Counselor of the Chinese Embassy inKenya, Yijun Zhang held a meeting on February 7, 2023 with Alex You, Global Marketing & Strategic Operations Director, andVincent Bi, Customer Service & Healthcare Informatics Director ofEdan Instruments, In...
Celltrion and LISCure Biosciences announce strategic collaboration to develop novel microbiome treatment for Parkinson's disease
* Co-research and co-development of novel microbiome therapeutics * Discovery of new candidates to meet high unmet medical needs in Parkinson's disease SEOUL, South Korea, Feb. 20, 2023 /PRNewswire/ -- LISCure Biosciences Inc., a clinical-stage biotech developing advanced microbiome technology...
Daewoong Pharmaceutical Reaches Sales of KRW 1.16 Trillion in 2022, Fexuclue Leads The Highest Revenue
- Hitting a record high sale with business profits of KRW 106 billion and net profits ofKRW 80.1 billion according to the accounting of 2022 - Not only stable positioning of Fexuclue but also achievement obtaining a permit of new medicine for Envlo SEOUL, South Korea, Feb. 19, 2023 /PRNewswire/ ...
GC Biopharma Receives WHO Pre-Qualification for BARYCELA
YONGIN, South Korea, Feb. 19, 2023 /PRNewswire/ -- GC Biopharma (006280.KS), a leading provider of biopharmaceutical products inSouth Korea, announced today that the World Health Organization (WHO) has granted prequalification for BARYCELA, GC Biopharma's varicella vaccine. WHO prequalificatio...
Qilian International Holding Group Ltd Declares Special Cash Dividends to Shareholders
JIUQUAN, China, Feb. 16, 2023 /PRNewswire/ -- Qilian International Holding Group Ltd (the "Company" or Nasdaq: QLI), aChina-based pharmaceutical and chemical products manufacturer, announced today that the Company has declared a special one-time cash dividend of$0.05 per ordinary share, payable i...
GLOBAL SARCOMA THERAPY NOW APPROVED FOR NEW ZEALAND PATIENTS
* Globally regarded soft-tissue sarcoma therapy has been approved by Medsafe forNew Zealand patients * YONDELIS® (trabectedin) demonstrates 45% reduction in risk of disease progression or death versus dacarbazine[1] SINGAPORE and AUCKLAND, New Zealand, Feb. 16, 2023 /PRNewswire/ -- Independen...
111, Inc. Hosts Hua Medicine Launches First Official Flagship Store
SHANGHAI, Feb. 16, 2023 /PRNewswire/ -- On February 15, 2023, 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company inChina, announced that during the HuaTangNing® Market Launch for Innovative Commerce Cooperation, Dr.Yu Gang, Co-founder and Executive...
Randomized Controlled Trial Backs Clinical Efficacy of Lunit AI for Chest X-Ray
* First-ever randomized controlled trial regarding deep learning-based AI in radiology provides strong evidence for the clinical value of AI * Large-scale study with 10,476 patients published in Radiology, the top journal in radiology SEOUL, South Korea, Feb. 13, 2023 /PRNewswire/ -- Findings ...
B dot Medical to Install Ultra-compact Proton Therapy System at Thammasat University in Thailand
- Responding to Growing Needs for Urban-type Proton Therapy in Thailand - TOKYO and BANGKOK, Feb. 13, 2023 /PRNewswire/ -- B dot Medical Inc. and Thammasat University, a leading national university in Thailand, have signed a memorandum of understanding to install the ultra-compact proton therapy ...
HanAll Biopharma Invests in Interon to Seek Collaboration Opportunities
* HanAll will invest in Interon Laboratories, a preclinical-stage biotechnology company focused on treating complex neurological disorders * Interon is developing a new category of immunotherapy for people with neurological and immune disorders starting with autism spectrum disorder SEOUL, So...
Nona Biosciences Enters into HCAb Based Antibody Discovery Collaboration Agreement with Mythic Therapeutics
CAMBRIDGE, Mass., Feb. 10, 2023 /PRNewswire/ -- Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Limited committed to cutting edge technology innovations, and providing a total solution from "Idea to IND" ("I to ITM"), today announced that it has entered into a collaboration agreement ...
US based COBRA diagnostic prostate cancer trial reaches recruitment target
SYDNEY, Feb. 9, 2023 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce its diagnostic 64Cu SAR-...
Technoderma Medicines Initiates TDM-180935 Atopic Dermatitis Clinical Program with Phase 1 Dose Escalation Trial
SAN DIEGO, Feb. 9, 2023 /PRNewswire/ -- Technoderma Medicines, Inc. ("the Company"), a clinical stage biopharmaceutical company, is pleased to report the Company has begun dosing healthy volunteer subjects in its Phase 1 clinical trial of topical TDM-180935 ointment. This first clinical trial in ...
AnPac Bio-Medical Science Enters into Definitive Agreement to Acquire Fresh2 Ecommerce Inc, a B2B Asian Food E-commerce Platform
Transaction expected to fuel the Company's growth in the U.S. food market NEW YORK, Feb. 9, 2023 /PRNewswire/ -- AnPac Bio-Medical Science Co., Ltd. (the "Company") (NASDAQ: ANPC), a company with operations inthe United States andChina focused on early cancer screening and detection and plans to ...
First Prescription for COSELA® (trilaciclib) Issued in China
- COSELA®, the world's first and only myeloprotection drug, was prescribed in Jilin Cancer Hospital onJanuary 28, 2023 - Simcere delivers drug to patients in 908 days from execution of license agreement to first prescription NANJING, China, Feb. 9, 2023 /PRNewswire/ -- Simcere Pharmaceutical Gr...
Week's Top Stories
Most Reposted
Protiviti Transforms Cyber Risk Consulting with CYFIRMA's Advanced Intelligence-Led Cybersecurity
[Picked up by 323 media titles]
2024-04-15 09:00Sephora appoints Xia Ding as Managing Director of Sephora Greater China
[Picked up by 302 media titles]
2024-04-15 17:33AI-DOL: Revolutionising the Future of Entertainment with AI-Powered Virtual Idols
[Picked up by 295 media titles]
2024-04-12 15:14LEGOLAND® School Challenge 2024 Expands Across Asia and Opens for Registration on April 15th
[Picked up by 275 media titles]
2024-04-11 11:00Allianz Partners Introduces Instant Online Chat for HCF Travel Insurance Customers
[Picked up by 275 media titles]
2024-04-15 08:00